Profil
J.
Henri Bayle worked as the Vice President-Research at Bellicum Pharmaceuticals, Inc. from 2014 to 2023.
Prior to that, he obtained an undergraduate degree from the University of Alberta and a doctorate degree from Princeton University.
Ehemalige bekannte Positionen von J. Henri Bayle
| Unternehmen | Position | Ende |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2023 |
Ausbildung von J. Henri Bayle
| Princeton University | Doctorate Degree |
| University of Alberta | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
